FemTech biotech & women's health

01Overview and value chain#

Markers EC: EU Gender Equality Strategy & IVDR 2017/746 | OECD: Biotech & health — women’s health biotechnology | Regulator: FDA (USA), EMA (EU), NMPA (China)

FemTech biotech develops biologics, drugs and diagnostics for conditions that affect exclusively or disproportionately women, targeting a medical gender gap where endometriosis alone affects roughly 10% of reproductive-age women yet historically took 7–10 years to diagnose through invasive laparoscopy. The 2026 frontier concentrates on four directions: non-invasive endometriosis diagnostics from saliva miRNA (Ziwig Endotest, fast-track reimbursed for 25,000 patients across 80 French medical centres since February 2025, reading 109 miRNA markers with reported above-95% diagnostic accuracy in the ENDOmiRNA study); ovarian-longevity and fertility therapeutics that slow ovarian ageing to extend the natural fertility window and defer menopause; vaginal-microbiome live biotherapeutic products (LBPs) built on Lactobacillus crispatus consortia to restore an acidic vaginal pH below 4.5 and prevent bacterial vaginosis and preterm birth; and next-generation non-invasive prenatal testing (NIPT) that sequences cell-free fetal DNA (cfDNA) from maternal blood, where BGI’s NIFTY has analysed more than 10 million pregnancies. The stack is regulated end-to-end — FDA drugs and devices in the US, the EU In Vitro Diagnostic Regulation (IVDR 2017/746) Class C for miRNA tests plus EMA for therapeutics in Europe, and NMPA registration in China.

The key directions of FemTech biotech & women’s health are:

1. Non-invasive endometriosis diagnostics: saliva miRNA sequencing and menstrual-blood liquid biopsy (Ziwig Endotest, NextGen Jane Smart Tampon) that replace diagnostic laparoscopy with a mail-in lab test returning a staged diagnosis in days.
2. Ovarian-longevity and fertility therapeutics: target discovery and non-hormonal drug design (Celmatix Resolve platform, now partnered with Gedeon Richter) to slow ovarian ageing, protect the follicle pool during chemotherapy, and defer menopause.
3. Vaginal-microbiome live biotherapeutics: L. crispatus consortia formulated as lyophilized vaginal LBPs (Novonesis/Lactobio) to restore a healthy acidic microbiome and reduce bacterial-vaginosis and preterm-birth risk.
4. Non-invasive prenatal testing (NIPT): high-throughput cfDNA sequencing of fetal DNA in maternal blood (BGI NIFTY) to screen for fetal chromosomal aneuploidies early in pregnancy.

Sectoral value chain#

[Sample sourcing] ──> [Omics profiling] ──> [AI biomarker decoding]
      │                     │                       │
(saliva, menstrual,     (RNA-seq, cfDNA)    (miRNA → disease score)
 venous blood kits)                                   │
                                                       ▼
[Clinical delivery] <─── [GMP formulation] <─── [Therapeutic R&D]
(reimbursement, CE-IVD)     (LBP, peptide)     (ovarian, microbiome)

Value chain levels#

Cross-cutting technologies of the sector:

• Saliva miRNA liquid biopsy: high-sensitivity profiling of non-coding microRNAs carried in salivary exosomes; a 109-miRNA panel reports endometriosis with diagnostic accuracy above 95%, replacing invasive laparoscopy with a mail-in test.
• L. crispatus live biotherapeutics: vaginal LBPs built on L-microbe-producing L. crispatus strains that hold vaginal pH below 4.5, blocking colonization by pathogenic anaerobes and cutting the risk of ascending reproductive infections and preterm birth.
• Anti-Müllerian hormone (AMH) engineering: recombinant AMH molecules and receptor agonists that temporarily place the ovary in a dormant state during chemotherapy or to control ovarian reserve, preserving female fertility.

02US#

The United States holds the deepest FemTech venture base and the largest dedicated women’s-health pharma, commercializing ovarian-longevity therapeutics and molecular tampons while NIH grants de-risk early diagnostics.

Ovarian-longevity R&D, molecular tampon, dedicated FemTech pharma, NIH funding#

• Celmatix and ovarian longevity: Celmatix’s Resolve platform uses multi-omic and clinical big data to map ovarian reserve and design non-hormonal candidates against ovarian ageing, and Hungarian pharma Gedeon Richter has acquired Celmatix’s women’s-health drug-discovery portfolio spanning fertility and endometriosis programs.
• NextGen Jane (Smart Tampon): NextGen Jane turns an ordinary tampon into a liquid-biopsy device, isolating endometrial cells and extracellular RNA from menstrual blood for non-invasive endometriosis and fibroid diagnosis; it validated a DNA/RNA/microbiome menstrual system in 2025 and received its second NIH SBIR Direct-to-Phase-II grant in May 2025.
• Organon (NYSE: OGN): spun out of MSD/Merck in 2021, Organon is the largest dedicated women’s-health company, reporting $6.2 billion in full-year 2025 revenue and $1.91 billion adjusted EBITDA (30.7% margin), with the postpartum-haemorrhage Jada System and the Nexplanon contraceptive implant.

03CN#

China develops FemTech under explicit state policy to support fertility and cut maternal and infant mortality, with BGI Genomics running the world’s largest non-invasive prenatal testing programme and CAS institutes researching premature ovarian insufficiency.

NIPT leadership (BGI Genomics), CAS reproductive institutes, vaginal probiotics#

• BGI Genomics (NIFTY): BGI Genomics’ NIFTY cfDNA test has analysed more than 10 million pregnancies worldwide, screening fetal trisomies (including Down syndrome) from maternal-blood cfDNA, and the upgraded NIFTY version has entered NMPA priority review.
• CAS reproductive institutes: the Shanghai institutes of the Chinese Academy of Sciences coordinate research into premature ovarian insufficiency (POI) and early menopause, and Chinese clinics run trials of collagen-scaffold mesenchymal-stem-cell therapy to regenerate the endometrium after injury.
• Vaginal-probiotic production: Chinese manufacturers produce large volumes of reproductive-health probiotics and are writing vaginal-microecology standards into national gynaecology guidelines.

04EU#

The European Union is the global regulatory and technological pioneer of non-invasive endometriosis liquid biopsy, pairing the breakthrough Ziwig salivary test with strict IVDR Class C oversight and a live-biotherapeutic pipeline from Novonesis.

Ziwig Endotest (France), Novonesis/Lactobio (Denmark), CE-IVDR Class C#

• Ziwig Endotest: the French biotech Ziwig built the first salivary endometriosis test, sequencing 109 salivary miRNA markers and decoding them with AI; France granted fast-track reimbursement for 25,000 patients across 80 medical centres in February 2025, and the ENDOmiRNA study — the largest saliva-biomarker study worldwide — confirmed its accuracy in December 2025.
• Novonesis (ex-Lactobio), Denmark: Novonesis (which absorbed the Lactobio team via Chr. Hansen) runs a multi-strain L. crispatus vaginal synbiotic programme, with a randomized placebo-controlled trial (NCT05659745) and the VIBRANT Phase 1 trial of L. crispatus live biotherapeutics for bacterial vaginosis, using machine learning to predict probiotic function from vaginal strains.
• IVDR Class C: European regulators classify early miRNA diagnostics under the IVDR 2017/746 as Class C, requiring exhaustive multi-centre validation studies and independent notified-body audit before CE marking — the bar Ziwig cleared for its reimbursement.

05Leading companies and research institutes#

06Tech stack and innovations#

The FemTech biotech stack joins a small-RNA/cfDNA sequencing core, an AI biomarker-decoding layer, and a live-biotherapeutic formulation layer.

1. Small-RNA (miRNA) extraction and NGS library preparation:
   • Silica magnetic nanoparticles with tuned porosity capture the delicate 19–24-nucleotide miRNA fraction while washing away ribosomal and genomic RNA, and a Pippin-Prep-style preparative gel electrophoresis size-selects the 140–160 bp miRNA-plus-adapter library, stripping PCR adapter-dimer contamination.
2. AI miRNA-signature decoding:
   • A trained machine-learning model (SVM / random forest) takes the normalized expression of the 109-miRNA endometriosis panel and outputs a disease probability, stage and phenotype, turning a saliva sample into a clinical diagnosis without laparoscopy.
3. Lyophilized L. crispatus live biotherapeutics:
   • L. crispatus biomass is freeze-dried with protectant sugars (trehalose, sorbitol) on a temperature profile that prevents acid damage to cell walls, holding a stable titre above 1 billion CFU per suppository for ambient storage.

07Value chains and production pipelines#

Diagnostic miRNA pipeline of the Ziwig Endotest (ISO 13485 / GMP)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Saliva collection into │ ───> │ 2. Automated total +      │
│    RNA-stabilizer tube    │      │    small-RNA extraction    │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Precision size-        │ <─── │ 3. Small-RNA library prep │
│    selection (gel)        │      │    (adapter ligation, RT)  │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. NGS sequencing         │ ───> │ 6. AI 109-miRNA score &   │
│    (Illumina NextSeq)     │      │    clinical report        │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Saliva collection and transport

The patient spits into a Ziwig Endotest tube; on cap-rotation a stabilizing buffer of chaotropic salts and RNase inhibitors is released, instantly denaturing salivary proteins and preserving exosomal extracellular RNA, and the tube is mailed to the central accredited laboratory.

Stage 2: Automated total and small-RNA extraction

A robotic liquid handler (e.g. Hamilton Microlab) transfers stabilized saliva to an extraction plate; isopropanol and silica magnetic beads bind RNA in chaotropic salt, three alcohol washes remove salts, proteins and mucins, and RNA is eluted in RNase-free water with quality checked on an Agilent Bioanalyzer for a crisp small-RNA peak.

Stage 3: Small-RNA library preparation

A T4 RNA ligase attaches a 3’ and then a 5’ single-stranded RNA adapter to the small-RNA fraction; reverse transcription synthesizes cDNA, and 15 cycles of PCR with unique TruSeq index primers barcode each patient’s library.

Stage 4: Precision size selection

The PCR product is loaded onto a preparative gel-electrophoresis system (e.g. Pippin Prep); a built-in laser detects DNA fragments migrating through agarose, and at 140–160 bp the instrument switches current to collect the clean miRNA-library fraction while discarding adapter dimers at about 120 bp.

Stage 5: NGS sequencing

Purified libraries are quantified by qPCR, up to 96 patient libraries are pooled equimolarly, denatured, and loaded on an Illumina NextSeq 550 flow cell for single-end 50 bp sequencing at a depth of at least 5 million reads per sample.

Stage 6: AI signature and clinical report

Reads are demultiplexed, adapter-trimmed, quality-filtered and aligned to the miRBase small-RNA database and the hg38 reference; a count matrix of the 109-miRNA panel is fed to a trained SVM model that outputs endometriosis probability, stage and phenotype; a clinical geneticist verifies the report and returns it to the gynaecologist, often sparing the patient a diagnostic laparoscopy.